Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its transition from a development-stage biotechnology company to a commercial-stage biopharmaceutical firm. The company’s lead product, LYMPHIR™, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma (CTCL), has generated $5.6 million in net revenue during the first six months of fiscal 2026, following its commercial launch in December 2025. This initial commercial success underscores the company’s ability to execute on its strategy of bringing first-in-class critical care products to market.
LYMPHIR™ (denileukin diftitox-cxdl) was approved by the U.S. Food and Drug Administration in August 2024 for adults with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin. The therapy is an engineered fusion protein combining interleukin-2 and diphtheria toxin, designed to target cells expressing IL-2 receptors. Since its commercial launch, LYMPHIR™ has achieved broad payer coverage, with nearly 100% of covered commercial lives and 83% of targeted accounts having formulary inclusion or under active review as of May 2026. The company also reported an initial shipment to Europe in April 2026, expanding its international footprint.
The company’s pipeline includes Mino-Lok®, a late-stage antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients who depend on central venous catheters for treatment. Mino-Lok® met its primary and secondary endpoints in a pivotal Phase 3 superiority trial, and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. With no FDA-approved therapies currently indicated for salvaging infected catheters, Mino-Lok® addresses a significant unmet medical need and has an estimated worldwide sales potential of approximately $1.8 billion.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products specifically for this condition, Halo-Lido could become the first such product if approved. The company completed a Phase 2b study in 2023 and has engaged with the FDA on next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) as a potential therapy for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies are planned to inform future human clinical trials.
The commercial performance of LYMPHIR™ is a key indicator of the company’s growth trajectory. With gross margins of approximately 80% on LYMPHIR™ sales, the product is contributing to the company’s financial stability. The company’s experienced leadership team, including CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings decades of pharmaceutical development, commercialization, and sales expertise.
Overall, Citius Pharmaceuticals is positioning itself as a diversified biopharmaceutical company with multiple near-term and long-term catalysts. The combination of a revenue-generating oncology product, a late-stage anti-infective with significant market potential, a potential first-in-class hemorrhoid treatment, and an innovative stem cell platform provides multiple avenues for value creation. As the company continues to advance these programs and expand LYMPHIR™ into additional oncology indications, it is poised to make a meaningful impact on critical care medicine.
